Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication.

ABSTRACT: Drug-drug interactions are of significant concern in clinical practice in oncology, particularly in patients receiving Cyclin-dependent kinase (CDK) 4/6 inhibitors, which are typically exposed to long-term regimens. This article presents the highlights from the 'First Workshop on Pharmacology and Management of CDK4/6 Inhibitors: Consensus about Concomitant Medications'. The article is structured into two modules. The educational module includes background information regarding drug metabolism, corrected QT (QTc) interval abnormalities, management of psychotropic drugs and a comprehensive review of selected adverse effects of palbociclib and ribociclib. The collaborative module presents the conclusions of the five working groups, each of which comprised five experts from different fields. F

SUBMITTER: Bellet M 

PROVIDER: S-EPMC6535716 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature